Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals

IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. The co-promotion agreement will enable Urovant to leverage Sunovion’s commercial infrast